Apyx Medical
APYX
Apyx Medical (APYX) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Initiated Coverage | Buy | $7.00 | Jul 13, 2026 |
| BTIG | Upgraded | Neutral → Buy | $6.00 | Mar 11, 2026 |
| Craig-Hallum | Maintained | Buy | $6.00 from $5.00 | Mar 11, 2026 |
| Roth Capital | Initiated Coverage | Buy | $6.00 | Dec 16, 2025 |
| Citizens | Upgraded | Market Perform → Market Outperform | $8.00 | Nov 12, 2025 |
| BTIG | Initiated Coverage | Neutral | — | Oct 17, 2024 |
| JMP Securities | Maintained | Market Perform | — | Sep 16, 2024 |
| Stephens & Co. | Maintained | Overweight | $5.00 from $8.00 | Nov 10, 2023 |
| Stephens & Co. | Initiated Coverage | Overweight | $8.00 | Jul 14, 2023 |
| Lake Street | Maintained | Buy | $9.00 from $6.00 | Jun 15, 2023 |
| JMP Securities | Maintained | Market Perform | — | May 24, 2023 |
| Lake Street | Maintained | Buy | $6.00 from $5.00 | May 12, 2023 |
Frequently asked questions
What is the latest analyst rating on APYX?
On Jul 13, 2026, HC Wainwright & Co. initiated coverage of Apyx Medical at Buy with a price target of $7.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.